Accord BioPharma Inc, the US specialty division of India-based Intas Pharmaceuticals Ltd, announced on Monday that Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from California-based Coherus BioSciences Inc, a commercial-stage biopharmaceutical company.
A biosimilar to Neulasta (pegfilgrastim), UDENYCA expands the company's portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry. It is available in three administration options -- autoinjector (AI), on-body injector (OBI) and prefilled syringe (PFS) -- to provide flexibility for patients to receive their treatment at home, on-the-go or in the office.
Following the acquisition, Accord BioPharma will continue to make UDENYCA available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer